After Demand Climbed With COVID-19, Abbott Expects Continued Nutritional Line Sales Growth
Post-Pandemic OTC Diagnostics Sales Also Look Promising To Firm
Executive Summary
CEO Robert Ford says “dynamics” of more consumers fortifying their diets to promote immunity from COVID-19 “are driving strong growth for our Ensure and Glucerna brands.” Analysts don't share Ford's confidence, though, for continued OTC diagnostics sales growth.
You may also be interested in...
HBW Executive Decisions: Clasado Sales Heads, CRN Scholars, PanTheryx Early Nutrition SVP
Clasado appoints APAC, EMEA and North America sales directors; CRN, American Society for Nutrition award students; DSM Veteran joins PanTheryx as early life nutrition SVP; Ford chairs Abbott board as White leaves; and turnover at Turning Point helm.
OTC COVID-19 Tests Have Abbott Seeing Continuing Demand For At-Home Diagnostics
“We see this is a as a significant opportunity, and quite frankly, a trend that's been happening overseas and is kind of now happening here in the US,” says Abbott Labs CEO Robert Ford.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.